Cytogen Corp. said Wednesday that three patientsdemonstrated tumor responses, including two completeremissions lasting two years, in Phase I studies of its OncoRad103 therapeutic for ovarian cancer.
The monoclonal antibody is linked to yttrium 90. ThePrinceton, N.J., company plans to file this fall to begin Phase IItrials in patients with less advanced disease to demonstrateconsistent therapeutic effects.
Cytogen plans to seek fast-track approval of OncoRad from theFDA. About 21,000 American women will be diagnosed withthe cancer this year, according to the American Cancer Society,and about 13,000 of those women will die.
The stock (NASDAQ:CYTO) rose 13 cents to $17.88. Investigatorspresented data from the safety study of 18 patents at lastweek's meeting of the American Association for CancerResearch in San Diego.
(c) 1997 American Health Consultants. All rights reserved.